Neurotech to commence clinical study program this quarter
Finfeed
Archived
Feb 15, 2021
Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.